Curis Announces Worldwide Licensing Rights for IAP Inhibitor GDC-0917 From Genentech
November 28, 2012 at 06:43 AM EST
Curis (NASDAQ: CRIS ), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has licensed from Genentech, a member of the Roche Group, (OTC: RHHBY ), exclusive, worldwide rights for the development and commercialization of GDC-0917,
